OmniAb Inc
OABI1.980USD
+0.070+3.66%
Market hours （ET）Quotes delayed by 15 min
241.83MMarket Cap
LossP/E TTM
More Details of OmniAb Inc Company
OmniAb, Inc. offers a discovery platform that provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. The Company’s OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur features structural attributes of cow antibodies for complex targets. The Company's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic target antigens.
Company Info
Ticker SymbolOABI
Company nameOmniAb Inc
IPO dateOct 09, 2020
CEOMr. Matthew William (Matt) Foehr
Number of employees114
Security typeOrdinary Share
Fiscal year-endOct 09
Address5980 Horton Street
CityEMERYVILLE
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code94608
Phone15102507800
Websitehttps://www.omniab.com/
Ticker SymbolOABI
IPO dateOct 09, 2020
CEOMr. Matthew William (Matt) Foehr
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. John L. Higgins
Mr. John L. Higgins
Chairman of the Board
Chairman of the Board
2.85M
+0.71%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Executive Vice President - Finance, Chief Financial Officer
Executive Vice President - Finance, Chief Financial Officer
223.83K
-12.04%
Dr. Carolyn R. Bertozzi, Ph.D.
Dr. Carolyn R. Bertozzi, Ph.D.
Independent Director
Independent Director
75.54K
+36.01%
Mr. Steven (Steve) Love
Mr. Steven (Steve) Love
Independent Director
Independent Director
58.33K
+52.17%
Dr. Philip J. (Phil) Gotwals, Ph.D.
Dr. Philip J. (Phil) Gotwals, Ph.D.
Independent Director
Independent Director
--
--
Mr. Matthew William (Matt) Foehr
Mr. Matthew William (Matt) Foehr
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Charles Stuart Berkman, J.D.
Mr. Charles Stuart Berkman, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
--
--
Dr. Jennifer Cochran, Ph.D.
Dr. Jennifer Cochran, Ph.D.
Independent Director
Independent Director
--
--
Mr. Steven C. Crouse
Mr. Steven C. Crouse
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. John L. Higgins
Mr. John L. Higgins
Chairman of the Board
Chairman of the Board
2.85M
+0.71%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Executive Vice President - Finance, Chief Financial Officer
Executive Vice President - Finance, Chief Financial Officer
223.83K
-12.04%
Dr. Carolyn R. Bertozzi, Ph.D.
Dr. Carolyn R. Bertozzi, Ph.D.
Independent Director
Independent Director
75.54K
+36.01%
Mr. Steven (Steve) Love
Mr. Steven (Steve) Love
Independent Director
Independent Director
58.33K
+52.17%
Dr. Philip J. (Phil) Gotwals, Ph.D.
Dr. Philip J. (Phil) Gotwals, Ph.D.
Independent Director
Independent Director
--
--
Mr. Matthew William (Matt) Foehr
Mr. Matthew William (Matt) Foehr
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
License and milestone revenue
2.02M
48.65%
Service revenue
1.95M
46.82%
Royalty revenue
188.00K
4.53%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
License and milestone revenue
2.02M
48.65%
Service revenue
1.95M
46.82%
Royalty revenue
188.00K
4.53%
Shareholding Stats
Updated: Fri, Jul 25
Updated: Fri, Jul 25
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Avista Capital Holdings, LP
12.93%
Janus Henderson Investors
6.59%
Whitefort Capital Management, LP
5.98%
BlackRock Institutional Trust Company, N.A.
5.28%
Ash X LP
4.43%
Other
64.80%
Shareholders
Shareholders
Proportion
Avista Capital Holdings, LP
12.93%
Janus Henderson Investors
6.59%
Whitefort Capital Management, LP
5.98%
BlackRock Institutional Trust Company, N.A.
5.28%
Ash X LP
4.43%
Other
64.80%
Shareholder Types
Shareholders
Proportion
Investment Advisor
21.12%
Investment Advisor/Hedge Fund
18.89%
Private Equity
12.93%
Hedge Fund
10.53%
Individual Investor
6.24%
Corporation
5.31%
Research Firm
0.93%
Pension Fund
0.15%
Bank and Trust
0.09%
Other
23.80%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
347
93.30M
76.27%
-5.04M
2025Q1
359
87.33M
71.43%
-8.58M
2024Q4
365
89.85M
74.79%
-8.38M
2024Q3
394
90.25M
75.21%
-25.05M
2024Q2
389
89.07M
76.08%
-29.09M
2024Q1
378
93.24M
79.93%
-23.55M
2023Q4
374
92.06M
79.14%
-28.03M
2023Q3
352
92.71M
80.23%
-26.22M
2023Q2
337
91.30M
79.07%
-24.17M
2023Q1
319
89.47M
77.82%
-24.53M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Avista Capital Holdings, LP
15.82M
12.93%
--
--
Sep 30, 2024
Janus Henderson Investors
8.06M
6.59%
+97.91K
+1.23%
Mar 31, 2025
Whitefort Capital Management, LP
7.31M
5.98%
+3.40M
+86.81%
May 30, 2025
BlackRock Institutional Trust Company, N.A.
6.46M
5.28%
+62.83K
+0.98%
Mar 31, 2025
Ash X LP
1.09M
0.89%
+1.09M
--
Jun 12, 2025
The Vanguard Group, Inc.
5.18M
4.23%
+142.26K
+2.82%
Mar 31, 2025
Macquarie Investment Management
4.42M
3.62%
+122.07K
+2.84%
Mar 31, 2025
Foehr (Matthew W)
3.80M
3.1%
-13.61K
-0.36%
Apr 23, 2025
Dimensional Fund Advisors, L.P.
3.13M
2.56%
+106.04K
+3.50%
Mar 31, 2025
Higgins (John L)
2.85M
2.33%
+20.00K
+0.71%
Jun 17, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.03%
Invesco Nasdaq Biotechnology ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Fidelity Enhanced Small Cap ETF
0.01%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
View more
iShares Micro-Cap ETF
Proportion0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.03%
Invesco Nasdaq Biotechnology ETF
Proportion0.02%
ProShares Ultra Nasdaq Biotechnology
Proportion0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0.01%
Fidelity Enhanced Small Cap ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
